PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- Skin/Soft Tissue InfectionsMethicillin Resistant Staphylococcus Aureus (MRSA)
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1077
- Registration Number
- NCT00087490
- Locations
- π»πͺ
Pfizer Investigational Site, Valencia, Venezuela
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00005093
- Locations
- πΊπΈ
New England Medical Center Hospital, Boston, Massachusetts, United States
π¨π¦BC Cancer Agency, Vancouver, British Columbia, Canada
πΊπΈUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004861
- Locations
- πΊπΈ
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈIreland Cancer Center, Cleveland, Ohio, United States
πΊπΈSinai Hospital of Baltimore, Baltimore, Maryland, United States
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00003720
- Locations
- πΊπΈ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈKaplan Cancer Center, New York, New York, United States
πΊπΈJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- Methicillin Resistant Staphylococcus Aureus (MRSA)
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1225
- Registration Number
- NCT00084266
- Locations
Pfizer Investigational Site
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
- Conditions
- Malaria, Falciparum
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2008-11-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00084240
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
- Conditions
- Malaria, Falciparum
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 244
- Registration Number
- NCT00084227
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004071
- Locations
- πΊπΈ
St. Vincents Comprehensive Cancer Center, New York, New York, United States
πΊπΈComprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States
πΊπΈFlorida Cancer Specialists, Fort Myers, Florida, United States
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 750
- Registration Number
- NCT00083889
- Locations
- π¬π§
Pfizer Investigational Site, Sutton Surrey, United Kingdom
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00003293
- Locations
- πΊπΈ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States